1. Harvard Medical School and Brigham and Women’s Hospital, Boston, MA, USA;
2. Mallinckrodt Pharmaceuticals, Health Economics and Outcomes Research Department, Bedminster, NJ, USA;
3. Boston Strategic Partners Inc., Boston, MA, USA;
4. Mallinckrodt Pharmaceuticals, Medical Affairs Department, Bedminster, NJ, USA;
5. OptiStatim LLC, Longmeadow, MA, USA;
6. Employee of Mallinckrodt during the conduct of this study;
7. School of Pharmacy, University of Washington, Seattle, WA, USA